|
Open- Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer
NCT ID : 03686683
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID : 03684785
Phase : 1b/2
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Using Virtual Reality (VR) Models for Preoperative Planning
NCT ID : 03334344
Protocol Number : VR Models
|
Urology and Urologic Oncology
|
Linehan
|
|
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab
NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II
|
Urology and Urologic Oncology
|
Twardowski
|
|
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
NCT ID : 02922764
Protocol Number : RGX-104-001
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence
NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2
|
Urology and Urologic Oncology
|
Linehan
|
|
A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)
NCT ID : 03131960
Phase : 3
|
Brain Tumors & Neuroscience
|
Achrol
|
|
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT)
NCT ID : 03393000
Phase : 3
|
|
Kesari
|
|
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
NCT ID : 03515538
Phase : 2a
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Feasibility Study of the Nativis Voyager System in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM)
NCT ID : 03276268
Phase : Feasibility
|
Brain Tumors & Neuroscience
|
Barkhoudarian
|
|
A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03463265
Phase : 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT ID : 03633110
Phase : 1 and 2
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Twardowski
|
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Phase : IIB or IIIA
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Onugha
|
|
Phase I Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Pembrolizumab in Subjects with Advanced Melanoma
NCT ID : 02565992
Protocol Number : VLA-011 (20160939)
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Phase Ib Study of Intratumoral CAVATAK(TM) (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma
NCT ID : 02307149
Protocol Number : VLA-013 (20150760)
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Phase 1B, Multicenter, Open-Label Study Of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma
NCT ID : 02903069
Protocol Number : MRZ-112 (20161905)
Phase : Ib
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR Study)
NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : III
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas
NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Feasibility Study of the Nativis Voyager(TM) System in Patients with Recurrent Glioblastoma Multiforme (GBM)
NCT ID : 02296580
Protocol Number : NAT-101 (20141455)
Phase : Pilot/ Feasibility
|
Brain Tumors & Neuroscience
|
Barkhoudarian
|
|
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)
NCT ID : 3302234
Protocol Number : MK 3475-598
Phase : III
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Onugha
|
|
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy
NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II
|
Urology and Urologic Oncology
|
Wilson
|
|
An Open-Label Non-Randomized, Multicenter Phase 2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression
NCT ID : 02858895
Protocol Number : MDNA55-05
Phase : II
|
Brain Tumors & Neuroscience
|
Achrol
|
|
A Longitudinal Assessment of Tumor Evolution in Patients with Brain Cancer
NCT ID : 3425292
Protocol Number : JWCI-17-0801
Phase : N/A
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer
NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
NCT ID : 02646748
Protocol Number : INCB39110-107 (20160236)
Phase : Ib
|
Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
O'Day
|
|
ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
NCT ID : 3397394
Protocol Number : CO-338-085
Phase : II
|
Urology and Urologic Oncology
|
Twardowski
|
|
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD
NCT ID : 2285101
Protocol Number : BCT-100-005
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
